top of page

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

  • Writer: Recruiting
    Recruiting
  • Dec 1, 2018
  • 1 min read

Updated: Oct 4, 2022

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

SELIBORDARA

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma


Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.


Sponsor

ClinicalTrials.gov Identifier: NCT03589222

Official Title: An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma

First Posted : July 17, 2018

Click here for ClinicalTrials.gov

Drug: Selinexor

Drug: Daratumumab

Drug: Bortezomib

Drug: Dexamethasone

Locations

Europe

Spain

Posts Archive
bottom of page